EP3169400A1 - Application médicales et vétérinaires de lumière à des composés thérapeutiques - Google Patents

Application médicales et vétérinaires de lumière à des composés thérapeutiques

Info

Publication number
EP3169400A1
EP3169400A1 EP15821889.1A EP15821889A EP3169400A1 EP 3169400 A1 EP3169400 A1 EP 3169400A1 EP 15821889 A EP15821889 A EP 15821889A EP 3169400 A1 EP3169400 A1 EP 3169400A1
Authority
EP
European Patent Office
Prior art keywords
light
solution
fiber optic
therapeutic
optic cable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15821889.1A
Other languages
German (de)
English (en)
Other versions
EP3169400A4 (fr
Inventor
Paul DABNEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emods Technology LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/497,269 external-priority patent/US9579177B2/en
Priority claimed from US14/536,633 external-priority patent/US9504848B2/en
Priority claimed from US14/583,580 external-priority patent/US9931189B2/en
Priority claimed from US14/630,513 external-priority patent/US9700735B2/en
Priority claimed from US14/638,902 external-priority patent/US10016456B2/en
Priority claimed from US14/697,579 external-priority patent/US20160015745A1/en
Application filed by Individual filed Critical Individual
Publication of EP3169400A1 publication Critical patent/EP3169400A1/fr
Publication of EP3169400A4 publication Critical patent/EP3169400A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D9/00—Bandages, poultices, compresses specially adapted to veterinary purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0606—Mouth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0645—Applicators worn by the patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light

Definitions

  • the present invention generally relates to therapy including enhancement of chemical effects with light and more specifically to medical and veterinary applications of light to antimicrobial and antineoplastic chemicals including antimicrobial and antineoplastic solutions.
  • a device in one aspect of the present invention, includes a solution retainer adapted to retain a therapeutic solution against a tissue of a user; a fiber optic cable; a light source that connects with the fiber optic cable and provides a light of a predetermined wavelength to the fiber optic cable; and a light termination on the fiber optic cable that exposes the light to the therapeutic solution.
  • a formulation in another aspect of the present invention, includes a solution that includes an oxidizer; the therapeutic solution having an initial therapeutic effectiveness; and a light of a predetermined frequency that that undergoes a synergistic reaction with the oxidizer, thereby enhancing the initial therapeutic effectiveness of the solution.
  • FIG. 1 depicts an embodiment of a dental device according to the present invention
  • FIG. 2 depicts an embodiment of a container according to the present invention
  • FIG. 3 depicts an embodiment of a bowl according to the present invention
  • FIG. 4 depicts an embodiment of a full body suit according to the present invention
  • FIGs. 5A-5E depict embodiments of garments according to the present invention.
  • FIG. 6 depicts an embodiment of a helmet according to the present invention
  • FIG. 7 depicts a catheter according to the present invention
  • FIG. 8 depicts an embodiment of a horse blanket according to the present invention.
  • FIGs. 9A-9C depict embodiments of animal covers according to the present invention.
  • Embodiments of the present invention generally provide devices and therapeutic solutions for medical and veterinary applications of light to therapeutic compounds.
  • Embodiments of the present invention generally provide a drug having an effectiveness that is enhanced by shining light of a predetermined frequency onto the drug.
  • An embodiment of the present invention may provide a device to hold solutions in contact with tissues, such as flesh, teeth, or animal's flesh, while the tissues and solutions are simultaneously being exposed to certain wavelengths of light.
  • This device may have a component that amplifies the effect of the antimicrobial solutions by using a certain wavelength of light.
  • the antimicrobial, antineoplastic, or other therapeutic solution may or may not be light activated at any given time. When the light is on, the therapeutic solution is "supercharged" by the light. This synergistic effect eliminates or reduces more microbes than the solution acting alone.
  • Embodiments of a therapeutic solution may hold oxidizers, antimicrobials or antineoplastics in contact with tissues, such as a human's or animal's flesh, while the tissues and solution are simultaneously being exposed to certain wavelengths of light.
  • Embodiments may have a component that amplifies the effect of antimicrobial, antiviral, and antineoplastic solutions by using a certain wavelength of light. When the light is applied to the solution, the solution is
  • This synergistic effect eliminates or reduces more microbes or tumors than the solution acting alone. This may be accomplished by various means including light directly from a light source, or from a light source in combination with a dental tray or other tray or container, a mask, a bandage, a horse blanket or animal covering, or a device for applying antimicrobial or antineoplastic chemicals for therapy.
  • a device that holds certain therapeutic agents in close proximity to tissues, a synergistic effect can be created to destroy or inhibit microbial or neoplastic growth.
  • this device could be a tray designed to cover the teeth and gingival. This tray would emit certain wavelengths of light that when combined with certain antimicrobial and/or
  • antineoplastic solutions in the tray would cause a synergistic antimicrobial and/or antineoplastic effect.
  • the light could be produced, for example, from a light emitting diode (LED) or laser.
  • An external light source could be connected to the fiber optic cable in the solution holding apparatus with a fiber optic connection cable that may also include a fiber optic connection interface or plug.
  • Embodiments of the present invention may create another means to treat disease.
  • Super charging antimicrobial or antineoplastic solutions with certain wavelengths of lights may cause the solutions to eliminate or reduce microbes and/or neoplastic tissue at a higher percentage than the solution alone.
  • Embodiments may create a synergistic effect between certain wavelengths of light and antimicrobial and/or antineoplastic solutions that when applied to tissues eliminates or reduces disease causing microorganism sand or neoplastic tissue.
  • Embodiments of the present invention may consist of a solution-holding apparatus or medium that emits certain wavelengths of light into the solution. When this light and solution combination is applied to tissues, a synergistic effect is created that reduces or eliminates microorganisms and/or neoplastic tissue that cause disease.
  • the essential components are 1.
  • Embodiments may utilize blue light, or another certain predetermined wavelength of light that supercharges the solution, with an exposure from a few second to minutes.
  • Embodiments may also include an H202 solution, such as a gel, with concentration of 0.3 mM or any concentration of solution that is suitable such as an antimicrobial, antiviral, or antineoplastic agent or compound.
  • a "scalding chart” might indicate that water of
  • H202 Hydrogen peroxide
  • Alternate embodiments may include heating elements that warm and further super-charge the therapeutic solution.
  • a device may contain heating or cooling components or both.
  • an antimicrobial solution may be preheated to an ideal or optimal temperature before it is exposed to synergizing light or used at a pH that may or may not vary.
  • Hydrogen peroxide may preferably be exposed to a light of 400-500 nanometers at 57 degrees Celsius (134 degrees F) for less than 20 seconds.
  • Other chemicals may have different preferred temperatures and pH.
  • Embodiments of a medical or veterinary device may include integrated or internal heating elements that run adjacent to the light emitting cable in the device.
  • Embodiments of integrated heating elements may be located in only a portion of the device, such as at the bottom of a container, garment, or cover. Heating elements may draw power from the same source as the light source, such as batteries or wall power. Power may be supplied to the heating elements in the device through the fiber optic connection cable or through a power connection cable that runs alongside the connection cable.
  • heating elements may be separate from the portion of the device that retains the therapeutic solution. Separate heating elements may warm the therapeutic solution to an optimal temperature before the solution is added to the device, such as with a heating tray or oven, or may be used to apply heat to the antimicrobial and/or antineoplastic solution in place, such as with a hot iron or wire.
  • Embodiments of a device may include a light emitting fiber optic cable that may expose the therapeutic solution to a certain wavelength of light, such as a purposefully selected wavelength or frequency of light from an LED or laser.
  • a cover may hold the antimicrobial solution.
  • An embodiment may include a plurality of light terminations or other light emitters on the light emitting fiber optic cable. Each light termination taps into the fiber optic cable to pipe some of the light out the end of the termination, thereby emitting light into the therapeutic solution.
  • the device may be adjustable, so that the terminations can be added or moved, or the quantity and locations of the light terminations may be measured to fit an individual user.
  • the light terminations may be located within or on the surface of the cover so that each light termination is will be positioned in a preselected location within the retainer, such as near portions of tissue to be treated.
  • the fiber optic cable may be opaque with light emitters spaced along its length, or may be at least partially translucent to emit light along its length.
  • a user may be a human or an animal.
  • a fiber optic cable may connect to a light source through a fiber optic connection cable.
  • the connection cable may enter the retainer or cover and optically connect with the fiber optic cable through a fiber optic connection interface so that the light source can be attached and removed after use.
  • An embodiment of the interface may include a fiber optic connection cable fixed to the fiber optic cable.
  • Another embodiment of the interface may include a socket that mates with a plug on the connection cable so that the light source can be attached and removed after use.
  • An embodiment may include a device with a light source and antimicrobial and/or antimicrobial solution.
  • Embodiments may include various human or animal body or body part coverings.
  • An embodiment of the present invention may include a retainer or covering that applies the therapeutic solution to a human, horse or other animal.
  • the retainer may be connected to a light source.
  • Embodiments may contain a multitude of fiber optic terminations, retainer may have a heating element.
  • Embodiments of a retainer may include: a dental tray that retains an antimicrobial, antineoplastic, or other therapeutic solution against a user's teeth; a medical solution retainer adapted to retain an antimicrobial or antineoplastic solution against a human user's tissue; a bucket or container; a bowl; a full body suit; an arm sleeve; a glove; a leg stocking; a toe cap; a helmet; a catheter tube; a medical or therapeutic solution retainer adapted to retain an antimicrobial or antineoplastic solution against an animal's tissue; a blanket for horses or other animals; or a covering for limbs or parts of an animal.
  • Embodiments may include a fiber optic cable that wraps around the inside surface of the device.
  • the fiber optic cable may have light terminations spaced along the fiber optic cable inside the device.
  • An embodiment may include a heating element inside the device.
  • the heating element may include heating wires inside the device that run adjacent to the fiber optic cable.
  • the fiber optic cable may connect through a connection cable to a light source.
  • a connection interface or plug may connect and release an external light source from the device.
  • the heating element may receive power from the light source, through the same light source connection cable or through a separate power connection cable.
  • a switch may allow the light source, the heating power, or both to be connected yet switched on or off.
  • a therapist may apply a therapeutic solution to the inside of the device, then put the device on a human or animal to receive therapy.
  • the therapist may turn on the heater or light source or both.
  • Embodiments of a therapeutic solution may include an antimicrobial, antiviral, antineoplastic compound that is in contact with human or animal skin.
  • This solution may be in a liquid, gel, mist, cream or other appropriate form.
  • the solution may or may not be heated by the device.
  • Embodiments may or may not includes compounds that adjust the pH of the solution.
  • Embodiments may contain a light source emitting a light of certain wavelengths which may be 400-500nM. This light source may be hand help. The light source may be in contact with the therapeutic solution or it may be held or placed within an effective distance.
  • the combination of antimicrobial and/or antineoplastic solution and a certain wavelength of light may create a synergistic effect causing a reaction that is greater than the sum of the reaction of the components individually (a synergistic effect).
  • Embodiments of this combination of light of a certain wavelength and an antimicrobial and/or antineoplastic solution may be utilized to treat acne, actinic keratosis, or any other skin or systemic condition or disease.
  • the antimicrobial, antiviral, antineoplastic, or other therapeutic chemical may be exposed to a wavelength of light that creates a synergistic effect enhancing the effectiveness of the therapeutic chemical.
  • This synergistic effect causes a greater reduction in bacteria associated with bacteria or tumors associated with cancer than the applications of the therapeutic solution alone or the light alone.
  • a chemical may be used without a reservoir.
  • the chemical may be inserted directly into the body cavity and exposed to light by a fiber optic wand with a plurality of light emitting fibers.
  • Embodiments of a carrier or reservoir may be the solution itself or a gel. This gel could be inserted in a body cavity with a catheter and exposed to the synergizing light by the same catheter or a different catheter.
  • Delivery devices may include, but are not limited to, reservoirs, bandages, gels, solutions, head coverings, animal covers, wraps, socks, stockings, hats, helmets, mists, suits, tents, probes, or catheters.
  • Hydrogen peroxide can be either an oxidizing agent or a reducing agent.
  • H202 serves as an oxidizing agent
  • the oxygen is reduced to H20.
  • H202 serves as a reducing agent
  • the oxygen is oxidized to 02 and bubbles are noticed.
  • Embodiments of the present invention may utilize H202 and formulations of H202 as an oxidizing agent or a reducing agent to provide an antimicrobial effect, antineoplastic effect and/or antiviral effect.
  • a formulation or drug will include an "oxidizer" if it includes H202.
  • An embodiment of the drug consists of a number of ingredients that include light of certain wavelengths and chemicals that alone or in combinations inhibit, retard and/or stop microbial, and/or viral and/or neoplastic growth.
  • the drug may resemble antimicrobial and/or antiviral and/or antineoplastic chemicals in terms of its chemical and functionality profiles in vivo.
  • the drug may have light as one of its ingredients. It reliably produces antimicrobial and/or antiviral and/or antineoplastic like effects in humans and other animals at clinically prescribed doses.
  • H202 lauric acid, dodecanoic acid, topical antibiotics, topical anesthetics, nicotinic acid, nicotinamide, antimicrobials such as clindamycin phosphate, Methyl 7-chloro-6,7,8-trideoxy-6-(l- methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-l-thio-L-threo-a-D-galacto-octopyranoside 2- (dihydrogen phosphate), salicylic acid, sulfur, retinoids such as 6-[3-(l-adamantyl)-4-methoxy- phenyl] naphthalene-2-carboxylic acid, Alpha Hydroxy acids, tretinoin, borax, caprylic acid, capric acid, myristic acid and additional chemicals useful in said method.
  • antimicrobials such as clindamycin phosphate, Methyl 7-chloro-6,7
  • the dosage forms of the present invention may comprise a compound consisting of certain wavelengths of light and one or more of the following chemicals: H202, lauric acid, dodecanoic acid, topical antibiotics, topical anesthetics, nicotinic acid, nicotinamide, antimicrobials such as clindamycin phosphate, Methyl 7-chloro-6,7,8-trideoxy-6-(l-methyl-trans-4- propyl-L-2-pyrrolidinecarboxamido)- 1 -thio-L-threo-a-D-galacto-octopyranoside 2-(dihydrogen phosphate), salicylic acid, sulfur, retinoids such as 6-[3-(l-adamantyl)-4-methoxy-phenyl] naphthalene -2-carboxylic acid, Alpha Hydroxy acids, tretinoin, borax, caprylic acid, capric acid, myristic acid and additional chemicals useful
  • Embodiments of a target chemical may include a compound with one or more of an antimicrobial, a biocidal or a disinfectant.
  • Embodiments of an antimicrobial may include a chlorhexidine compound.
  • Embodiments of a target chemical may include a non-steroidal anti- inflammatory compound, such as, for example, an indene derivative.
  • Embodiments of a target chemical may include an iodine compound.
  • Embodiments of a target chemical may include a Tumor Necrosis Factor or a member of the TNF family of cytokines.
  • Embodiments of a target chemical may include a metal such as silver (Ag) or a transition metal such as Cu or Fe.
  • Embodiments of a target chemical may include an enzyme.
  • Embodiments of an enzyme may include one or more of protease, pectinase, or elastase.
  • Embodiments of a target chemical may include an antineoplastic.
  • Embodiments of a target chemical may include an antibiotic, such as, for example, ciprofloxacin.
  • Embodiments of a target chemical may include an antispasmodic, such as, for example, methylene bicloride.
  • a first reaction may include light of a certain wavelength, such as 400-500 nanometers, combined with an oxidizer, such as hydrogen peroxide.
  • the light plus oxidizer may be a treatment all by itself.
  • a second reaction may include light of a certain wavelength combined with an oxidizer, further combined with a target chemical undergoing a synergistic reaction.
  • Embodiments of a drug may include an oxidizer that has been light-enhanced, and a target chemical that has been light-enhanced, to provide a drug that has a light-enhanced therapeutic effectiveness.
  • the drug may be a solution that is held in contact with a user while the light is applied is applied from a light source, or the solution may be light-enhanced before application.
  • the light may include two frequencies of light that are applied to simultaneously applied to a drug or solution, or a first frequency of light may be applied and then a second frequency of light may be applied in series.
  • the selected target chemical may be used in combination with surfactants, wetting agents chelating agents, or useful ingredients.
  • Embodiments of medical drugs may be used in tablet, pill, capsule, gel, liquid, spray, mist, cream, or paste form. Embodiments may be used at varying temperatures to modulate their efficacy.
  • FIG. 1 depicts an embodiment of a dental device 10.
  • a light emitting fiber optic cable 12 may expose the antimicrobial solution 14 to a certain wavelength of light, such as a purposefully selected wavelength or frequency of light from an LED or laser.
  • a tray 16 may hold the antimicrobial solution 14.
  • An embodiment may include a plurality of light terminations 18 or other light emitters on the light emitting fiber optic cable 12. Each light termination 18 taps into the fiber optic cable 12 to pipe some of the light out the top of the termination, thereby emitting light into the antimicrobial solution 14.
  • the device may be adjustable, so that the terminations 18 can added or moved, or the quantity and locations of the light terminations 18 may be measured to fit an individual user.
  • the light terminations 18 may be located within the tray 16 so that each light termination 18 is will be positioned between adjacent teeth or adjacent to a tooth of the user.
  • the fiber optic cable may be opaque with light emitters spaced along its length, or may be at least partially translucent to emit light along its length.
  • the fiber optic cable 12 may connect to a light source 20 through a fiber optic connection cable 22.
  • the connection cable 22 may enter the tray 16 and optically connect with the fiber optic cable 12 through a fiber optic connection interface 24 so that the light source 20 can be attached and removed after use.
  • An embodiment of the interface 24 may include an aperture in a wall of the tray 16 with a fiber optic connection cable 22 fixed to the fiber optic cable 12.
  • Another embodiment of the interface 24 may include a socket on the tray 16 that mates with a plug on the connection cable 22 so that the light source 20 can be attached and removed after use.
  • an embodiment of a medical device 30 may include a container 32 having a wall 34, a bottom 36, and a carrying handle 38.
  • Embodiments may include a fiber optic cable 40 that wraps up the inner surface of the wall 34.
  • Light terminations 42 may be located on the fiber optic cable 40 inside the container.
  • a heating element 44 may be located around the bottom of the container 32.
  • the fiber optic cable 40 may connect to a light source 46 through a fiber optic connection cable 48.
  • an embodiment of a medical device 50 may include a bowl 52 with a fiber optic cable 54 that wraps around an inside surface 56 of the bowl 52.
  • the fiber optic cable 54 may have light terminations 58.
  • Embodiments may have a base 60, which may contain a heating element 62.
  • the fiber optic cable 54 may connect to a light source 64 through a fiber optic connection cable 66.
  • the light source 64 may include an off/off switch 68 or a timer control 69.
  • an embodiment of a medical device 70 may include a full body suit 72 having an integrated torso portion 74, sleeves 76, pants 78, feet 80, and a hood 82, and removable gloves 84 or mittens 86.
  • the sleeves 76 may have cuffs 88 to tighten against the user's wrists.
  • the hood 82 may have elastic portions 90 to tighten against the user's face.
  • Embodiments may include an input tube 92, such as on one shoulder of the torso portion 74, and an exhaust tube 94 on the opposite shoulder of the torso portion 74.
  • Embodiments may include a fiber optic cable 96 spaced along the inner fabric of the suit 72. Light terminations 98 may be located on the fiber optic cable 96 inside the suit 72.
  • a heating element may be embedded within the fabric of the suit 72.
  • the fiber optic cable 96 or heating element or both may connect to a light source through a fiber optic connection cable.
  • FIGs. 5A, 5B, 5C, 5D and 5E depict embodiments of medical devices including garments to carry light-enhanced antimicrobial solution to a user wearing the garment.
  • FIG. 5A depicts an embodiment of an arm sleeve 122.
  • FIG. 5B depicts an embodiment of a glove 124.
  • FIG. 5C depicts an embodiment of a toe cap 126.
  • FIG. 5D depicts an embodiment of a thigh-high stocking with a toe covering 128 or without a toe covering 130.
  • FIG. 5E depicts an embodiment of a one foot stocking 132 with waist band 134.
  • an embodiment of a medical device 140 may include a helmet 142 with a fiber optic cable 144 that wraps around an inside surface 146 of the helmet 142.
  • the fiber optic cable 144 may have light terminations 148.
  • Embodiments may include heating elements 150 which may include wires in a lining of the helmet.
  • the fiber optic cable 144 may connect to a light source 152 through a fiber optic connection cable 154.
  • Catheter As depicted in FIG.7, an embodiment of a medical device 160 may include a catheter 162 having a catheter tube 164, a mesh dispenser screen 166, and a fiber optic cable 168 having one or more light terminations 170.
  • a heating element 172 may be external to the catheter tube 164, and may provide heated antimicrobial solution 174 through an input tube 176.
  • a light source 178 may be connected through a fiber optic connection cable 180 to the fiber optic cable 168 with a fiber optic connection interface 182.
  • Horse blanket As depicted in FIG. 8, an embodiment of a full horse blanket
  • Embodiments may include a cover portion 202, a neck portion 204, and an upper legs portion 206.
  • a blanket 200 may include straps 208 to hold the cover closed.
  • the blanket 200 may be coated on the inside with an antimicrobial solution or gel.
  • Embodiments may include a fiber optic cable 210 that wraps around the inside surface the cover portion 202.
  • Embodiments may include a heating element 212, which may include heating wires inside the cover portion 202.
  • Embodiments may include a connection interface 214 that connects the fiber optic cable 210 to a light source 216.
  • Light terminations 218 may be located on the fiber optic cable 210 inside the blanket 200.
  • the light source 216 may have an on/off switch 220 or timer control .
  • an animal cover 230 may include a sheet 232 of soft plastic, and an attachment mechanism 234 at one end of the sheet 232.
  • the cover 230 may be wrapped around an animal's neck and the attachment mechanism 234 on one end of the sheet 232 may attach to the other end of the sheet 232 to form a loop.
  • Embodiments may include a soft fabric trim 46 at the top and bottom sides, where the cover 230 rubs against the animal or other objects.
  • the cover 230 may be coated on the inside with an antimicrobial solution or gel.
  • Embodiments may include a fiber optic cable 238 that wraps around the inside surface the sheet 232.
  • Embodiments may include a heating element 240, which may include heating wires inside the cover.
  • Embodiments may include a connection interface 228 that connects the fiber optic cable 238 to a light source 242.
  • Light terminations 244 may be located on the fiber optic cable 238 inside the blanket.
  • the light source 230 may have an on/off switch 246 or timer control.
  • Embodiments of a method of treating acne vulgaris may include administering a therapeutically effective amount of a peroxide solution with light of a certain wavelength range that may be used in combination with one or more other antimicrobials or other chemicals that may consist of topical antibiotic, topical anesthetic, nicotinic acid, nicotinamide, antimicrobials such as clindamycin phosphate, Methyl 7-chloro-6,7,8-trideoxy-6-(l-methyl-trans-4- propyl-L-2-pyrrolidinecarboxamido)- 1 -thio-L-threo-a-D-galacto-octopyranoside 2-(dihydrogen phosphate).
  • Embodiments of an antimicrobial may include salicylic acid, sulfur, retinoids such as 6- [3-(l-adamantyl)-4-methoxy-phenyl] naphthalene-2-carboxylic acid, glycolic acid, tretinoin, borax, and additional chemicals useful in said method.
  • retinoids such as 6- [3-(l-adamantyl)-4-methoxy-phenyl] naphthalene-2-carboxylic acid, glycolic acid, tretinoin, borax, and additional chemicals useful in said method.
  • Embodiments of topical and systemic agents may be utilized as therapeutic chemicals in embodiments of the present invention for the treatment of acne, including hydrogen peroxide, carbamide peroxide, sulfur, retinoids such as 6-[3-(l-adamantyl)-4- methoxy-phenyl] naphthalene-2-carboxylic acid, glycolic acid, borax, resorcinol, salicylic acid, benzoyl peroxide, vitamin A acid (tretinoin) and topical and systemic antibiotics.
  • Embodiments including combinations of various peroxide compounds with certain chemical agents may be effective in treating acne, and have a synergistic effect in treating acne that is greater than the effect expected by treatment with the individual agents themselves. This synergistic effect has an even greater synergistic effect when exposed to certain wavelengths of light.
  • the second chemical may be a therapeutic chemical or acne-therapeutic chemical because it contains elements which are helpful in reducing acne and are used in an acne treatment or acne-related therapy.
  • embodiments with hydrogen peroxide may kill 30% of bacteria that are exposed to it for 20 seconds.
  • Light of the wavelength 360nM - 500nM may kill 3% of bacteria that are exposed to it for 20 seconds.
  • Hydrogen peroxide in combination with light of 360nM - 500nM may exhibit a synergistic reaction that kills 96% of bacteria exposed to this combination for 20 seconds.
  • Formulations of the solutions used in embodiments of this invention may include combinations of hydrogen peroxide and/or carbamide peroxide and/or benzoyl peroxide and one or more of sulfur, retinoids such as 6-[3-(l-adamantyl)-4- methoxy-phenyl] naphthalene-2-carboxylic acid, glycolic acid, borax, resorcinol, salicylic acid, vitamin A acid (tretinoin) and topical and systemic antibiotics.
  • retinoids such as 6-[3-(l-adamantyl)-4- methoxy-phenyl] naphthalene-2-carboxylic acid
  • glycolic acid borax
  • resorcinol resorcinol
  • salicylic acid vitamin A acid (tretinoin)
  • topical and systemic antibiotics topical and systemic antibiotics.
  • topical solutions of hydrogen peroxide and/or carbamide peroxide and/or benzoyl peroxide and other chemicals deemed effective may be delivered in various organic vehicles or carriers.
  • Embodiments of carriers may include a
  • the active ingredient may present in the range of from about 0.001% to about 50% by volume of the carrier.
  • the pH of the solution may be adjusted so that tissue sensitivity is minimized while the effectiveness of the solution is not hampered.
  • the temperature of the solution may be adjusted to optimize its effectiveness.
  • a "scalding chart” might be provided or used. This chart may indicate that water of 130 degrees is safe under an exposure of 30 seconds, but over that it causes burns. Water of 120 10 degrees may be safe up to 5 minutes. Solutions warmer than normal body temperature will tend to open pores exposing bacteria to greater amounts of the solution. Systemic antimicrobial agents may be used as a part of an embodiment of this treatment to increase its effectiveness.
  • the solution may be exposed to light in a wavelength of 360 nM- 600 nM or any other wavelength that proves effective for a certain time that may range from 1 second to 1 minute.
  • Embodiments may include a solution that may be warmed, and light creates the synergistic effect that is unique to this invention. This light may be used in varying distances from the solution to modulate its synergistic effect.
  • topical solutions of peroxide compounds may include hydrogen peroxide and/or carbamide peroxide and/or benzoyl peroxide in various organic carriers in concentrations that may range from 0.001 to 50% by volume of the carrier.
  • the compounds may be incorporated into various vehicles or carriers including solutions, lotions, creams, gels, mists, pastes and ointments along with one or more of the following ingredients: nicotinic acid or nicotinamide that may be present in concentrations from 0.001% to 30% by volume of the carrier; erythromycin base in concentrations that may present from 0.001% to about 30% by volume of the carrier; clindamycin phosphateMethyl 7-chloro-6,7,8-trideoxy-6-(l- methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-l-thio-L-threo-a-D-galacto-octopyranoside 2- (dihydrogen phosphate).
  • nicotinic acid or nicotinamide that may be present in concentrations from 0.001% to 30% by volume of the carrier
  • erythromycin base in concentrations that may present from 0.001% to about 30% by volume of the carrier
  • Embodiments may have concentrations of from 0.001 to 30% by volume; tetracycline hydrochloride in concentrations of from 0.001 to 30% by volume of the carrier; retinoids such as 6-[3-(l-adamantyl)-4-methoxy-phenyl] naphthalene-2-carboxylic acid; and other ingredients deemed effective in treating acne vulgaris.
  • such carriers may be useful for the incorporation of carbamide peroxide and may include combinations of ethyl alcohol and propylene glycol, surface active agents such as lauryl ethers and lauryl esters, and other carriers effective for this invention. Applications of the carrier and effective ingredients may be made to the face or other infected areas of acne patients.
  • This treatment may be applied at varying intervals such as 1 to 4 times in a 24 hour period with the result that open and closed comedones (blackheads and whiteheads), and inflamed lesions are greatly reduced within a period of days to weeks varying with the number of applications per day.
  • Embodiments of the present invention may provide an improved method for the treatment of acne vulgaris involving the periodic application of an antimicrobial solution containing an effective amount of peroxide agents alone or in combination with one or more of a topical antibiotic, topical anesthetic, nicotinic acid, nicotinamide, antimicrobials, salicylic acid, sulfur, retinoids such as 6-[3-(l-adamantyl)-4-methoxy-phenyl] naphthalene -2-carboxylic acid, glycolic acid, tretinoin, borax, and additional chemicals useful in said method.
  • This antimicrobial solution may be applied to patients with the inflammatory disease, acne vulgaris.
  • the antimicrobial solution may be adjusted to a temperature that is optimal for this treatment.
  • the antimicrobial solution may be applied over the acne vulgaris lesions and associated inflamed tissue. Once applied, the antimicrobial solution may be exposed to a wavelength of light that creates a synergistic effect enhancing the effectiveness of the antimicrobial solution. This synergistic effect may cause a greater reduction in bacteria associated with acne vulgaris than the applications of the antimicrobial solution alone or the light alone.
  • Embodiments of a solution may contain a light activated pigment that may fluoresce when exposed to the wavelength of light used in the treatment. This pigment could indicate to the user that the synergistic effect is occurring.
  • EXAMPLE 1 a 3% solution of hydrogen peroxide in a gel carrier is prepared. Twice daily topical applications of this solution are administered to an infected area on a patient suffering from acne vulgaris. After application, the solution is exposed to a 360-500 nM wavelength of light for 20 seconds creating a synergistic effect that is greater than the application of the light or the solution alone. This light is applied by a LED device the exposes the patients entire infected area at one time. The solution is then rinsed off with clean water. After two weeks of treatment, the comedone count on the patient, and the inflamed areas that result from an acne infection will have measurably declined. This synergistic effect between the solution and the light is unique to this invention.
  • EXAMPLE 2 In another embodiment, a solution of containing 3% hydrogen peroxide, 3% benzoyl peroxide, and salicylic acid are combined in a carrier in cream form. This solution is buffered to a pH of 6. This cream is applied to areas infected with acne vulgaris on a patient one time per daily. Once the cream is applied, it is exposed to a 10 watt, hand help light emitting light in wave lengths from 410nM - 500nM thus creating a synergistic effect between the solution and the light causing a greater reduction in microbes then the light or the solution acting alone. The light may have a termination that radiates this light that is 15mm in diameter. This particular size would enable the patient to target small areas. The exposure time of the light is one minute. This embodiment of the invention may be used to maintain an area that once exhibited an active acne vulgaris infection. This synergistic relationship between the light and the solution is unique to this invention.
  • EXAMPLE 3 In yet another embodiment, a solution containing 15% carbamide peroxide, 2.5% clindamycin phosphateMethyl 7-chloro-6,7,8-trideoxy-6-(l-methyl-trans- 4-propyl-L-2-pyrrolidinecarboxamido)- 1 -thio-L-threo-a-D-galacto-octopyranoside 2-(dihydrogen phosphate).
  • Embodiments may include tretinoin are combined in a gel form carrier This carrier solution is heated to 105 degrees Fahrenheit. The warmed solution helps to open the patient's pores once it is applied to the infected area. This solution is applied three times per day.
  • the infected area is exposed to a light of 410nM - 500nM by a lamp that would expose an area with a diameter of 30 centimeters.
  • the infected area and solution are exposed to this certain wavelength of light for 30 seconds.
  • the synergistic effect of the light and solution that may be warmed is greater than the effect of the light or the solution acting individually. This synergistic effect between the light and the solution that may be warmed is unique to this invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Laser Surgery Devices (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

L'invention concerne des applications médicales et vétérinaires de lumière à des composés thérapeutiques utilisant un rétenteur de solution approprié pour retenir une solution thérapeutique contre un tissu d'un utilisateur, un câble à fibre optique, une source lumineuse qui se connecte au câble à fibre optique et fournit une lumière d'une longueur d'onde prédéterminée au câble à fibre optique, et un terminal lumineux sur le câble à fibre optique, qui expose la lumière à la solution thérapeutique. Un mode de réalisation comprend un oxydant, la solution thérapeutique ayant une efficacité thérapeutique initiale, et une lumière d'une fréquence prédéterminée qui est soumise à une réaction de synergie avec l'oxydant, ce qui permet d'améliorer l'efficacité thérapeutique initiale de la solution.
EP15821889.1A 2014-07-18 2015-07-07 Application médicales et vétérinaires de lumière à des composés thérapeutiques Withdrawn EP3169400A4 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201462026498P 2014-07-18 2014-07-18
US14/497,269 US9579177B2 (en) 2014-07-18 2014-09-25 Dental and medical devices with light source and antimicrobial solution
US14/536,633 US9504848B2 (en) 2014-07-18 2014-11-09 Medical devices with a light source and antimicrobial solution
US14/583,580 US9931189B2 (en) 2014-07-18 2014-12-26 Veterinary devices with a light source and antimicrobial solution
US14/630,513 US9700735B2 (en) 2014-07-18 2015-02-24 Medical and veterinary applications of light to antimicrobial and antineoplastic chemicals
US14/638,902 US10016456B2 (en) 2014-07-18 2015-03-04 Methods for treating acne vulgaris
US14/697,579 US20160015745A1 (en) 2014-07-18 2015-04-27 Formulations of Antimicrobial, Antiviral, and Antineoplastic Compounds In Combination With Certain Wavelengths of Light
PCT/US2015/039292 WO2016010765A1 (fr) 2014-07-18 2015-07-07 Application médicales et vétérinaires de lumière à des composés thérapeutiques

Publications (2)

Publication Number Publication Date
EP3169400A1 true EP3169400A1 (fr) 2017-05-24
EP3169400A4 EP3169400A4 (fr) 2018-04-11

Family

ID=55079906

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15821889.1A Withdrawn EP3169400A4 (fr) 2014-07-18 2015-07-07 Application médicales et vétérinaires de lumière à des composés thérapeutiques

Country Status (7)

Country Link
EP (1) EP3169400A4 (fr)
JP (1) JP2018501829A (fr)
KR (1) KR20170019383A (fr)
CN (1) CN106659902A (fr)
AU (1) AU2015290092B2 (fr)
CA (2) CA2954886C (fr)
WO (1) WO2016010765A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108853750B (zh) * 2018-07-16 2020-03-20 北京大学口腔医学院 穿戴式光疗设备
CN109009549B (zh) * 2018-08-20 2024-06-28 中国人民解放军军事科学院军事医学研究院 记录动物药物成瘾行为及相关脑区神经活动规律的装置
DE102020111257A1 (de) 2020-04-24 2021-10-28 Jessika Kähler Anordnung zur Photobiomodulation eines Lebewesens

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898439A (en) * 1988-02-10 1990-02-06 Kei Mori Light radiation device for use in medical treatment
AU3578497A (en) * 1996-08-08 1998-03-06 Light Sciences Limited Partnership Method and apparatus to treat gingival and periodontal disease
US6254391B1 (en) * 1997-11-22 2001-07-03 Daniel Henry Darnell Device for heating the teeth and uses therefor
CN1269468C (zh) * 2001-01-29 2006-08-16 三菱瓦斯化学株式会社 牙齿漂白剂和牙齿漂白方法
ATE525095T1 (de) * 2002-01-08 2011-10-15 Bernard Technologies Inc Antimikrobielle körperbedeckungsartikel
US6893259B1 (en) * 2004-03-08 2005-05-17 Igor Reizenson Oral hygiene device and method of use therefor
SG140589A1 (en) * 2004-08-06 2008-03-28 Pharos Life Corp Therapy device and related accessories, compositions, and treatment methods
GB0423332D0 (en) * 2004-10-21 2004-11-24 Dezac Ltd Tooth whitening apparatus and methods
JP2006271831A (ja) * 2005-03-30 2006-10-12 Terumo Corp 医療用治療装置およびその装置の使用方法
AU2006249760C1 (en) * 2005-05-25 2010-11-04 Biolase, Inc. Device having activated textured surfaces for treating oral tissue
CA2632183A1 (fr) * 2005-08-25 2007-03-01 Philip R. Houle Solutions sensibilisantes ameliorees, systemes, et procedes d'utilisation
US8057464B2 (en) * 2006-05-03 2011-11-15 Light Sciences Oncology, Inc. Light transmission system for photoreactive therapy
EP3205355A1 (fr) * 2008-11-07 2017-08-16 KLOX Technologies, Inc. Combinaison d'un oxydant et d'un photoactivateur
US8771741B2 (en) * 2009-01-23 2014-07-08 The Penn State Research Foundation In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
JP2012532103A (ja) * 2009-06-30 2012-12-13 スリーエム イノベイティブ プロパティズ カンパニー 光活性化抗菌性物品及び使用方法
JP6246468B2 (ja) * 2010-03-11 2017-12-13 メルク パテント ゲーエムベーハー 治療および化粧品におけるファイバー
US8591229B2 (en) * 2010-12-16 2013-11-26 Duane C. Keller Devices and methods for creating a positive pressure environment for treatment of oral biofilms associated with periodontal disease
US20150072302A1 (en) * 2013-04-19 2015-03-12 Jasibo, LLC. Light activated tooth whitening composition
US20150045720A1 (en) * 2013-08-08 2015-02-12 A-Z Ltd. Method for treating local infection

Also Published As

Publication number Publication date
AU2015290092B2 (en) 2018-08-16
WO2016010765A1 (fr) 2016-01-21
CN106659902A (zh) 2017-05-10
KR20170019383A (ko) 2017-02-21
CA2954886A1 (fr) 2016-01-21
EP3169400A4 (fr) 2018-04-11
CA2954886C (fr) 2020-06-30
JP2018501829A (ja) 2018-01-25
CA2985090C (fr) 2023-11-07
AU2015290092A1 (en) 2017-01-12
CA2985090A1 (fr) 2016-01-21

Similar Documents

Publication Publication Date Title
JP7311268B2 (ja) 光線力学療法のための局所用組成物、閉塞性ドレッシング材、それを用いたキット、光線力学療法材料、および光線力学療法のための方法
US9884203B2 (en) Medical and veterinary applications of light to antimicrobial and antineoplastic chemicals
US6443978B1 (en) Photomatrix device
KR102057349B1 (ko) 광 조사 기구
DK2545962T3 (en) irradiation Facilities
US20160015909A1 (en) System, retainer and method of providing therapeutic treatment for acne
CA2954886C (fr) Application medicales et veterinaires de lumiere a des composes therapeutiques
JP2018501829A5 (fr)
US10293148B2 (en) System, retainer and method of preventing and treating nosocomial infections including methicillin-resistant Staphylococcus aureus infections
US9504848B2 (en) Medical devices with a light source and antimicrobial solution
JP2018536028A (ja) 刺青の退色および除去を行うシステム、装置、および方法
US20160354407A1 (en) Formulations of Antimicrobial, Antiviral, and Antineoplastic Compounds In Combination With Certain Wavelengths of Light
CN105999265A (zh) 光敏分子的光动力组合在痤疮治疗药物中的应用
Hawk Sunbeds, as discussed in the very interesting article in today’s issue of this journal, are commercially available lie-on ultraviolet radiation (UVR)-emitting devices for use by the public for sunbathing and sun-tanning when this is not feasible outdoors. In spite of their similarities to sunlight, however, they have aston

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180309

RIC1 Information provided on ipc code assigned before grant

Ipc: A61N 5/06 20060101AFI20180306BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EMODS TECHNOLOGY, L.L.C.,

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DABNEY, PAUL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210831